← Back to Search

Other

Insomnia Therapy for Cardiovascular Disease Improvement (SHADES Trial)

N/A

Waitlist Available

Led By Jesse C Stewart, Ph.D.

Research Sponsored by Indiana University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Current insomnia disorder confirmed through Insomnia Severity Index (ISI) and Structured Clinical Interview for DSM-5 Sleep Disorders

Age ≥40 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 6 months

Awards & highlights

SHADES Trial Summary

This trial will test if an updated insomnia treatment improves CVD factors & if this is due to improved sleep. 200 participants will get either the treatment or an active control. Results will be measured for CVD factors & sleep.

Who is the study for?

This trial is for adults over 40 who are primary care patients at Eskenazi Health with insomnia and a higher risk of heart disease. They must have confirmed insomnia disorder and specific cardiovascular risk factors within the past five years, but can't join if they're pregnant, have severe cognitive issues, acute suicide risk, certain sleep restrictions or disorders like sleep apnea, bipolar disorder or psychosis, use CPAP machines for breathing at night, have had serious heart conditions or inflammatory diseases.Check my eligibility

What is being tested?

The SHADES clinical trial tests whether an updated insomnia treatment improves factors related to heart disease. It compares two groups: one receives the SHADES intervention (a mix of internet-based therapy, phone calls and face-to-face sessions) while the other gets standard care including sleep education. The goal is to see if better sleep reduces inflammation and other risks linked to heart problems in those with chronic insomnia.See study design

What are the potential side effects?

While this study focuses on behavioral treatments rather than medications which typically carry more side effects; potential discomforts may include inconvenience from frequent monitoring or stress from discussing personal health issues during therapy sessions.

SHADES Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with insomnia.

Select...

I am 40 years old or older.

SHADES Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

High-Sensitivity C-Reactive Protein (hsCRP)

Secondary outcome measures

Hemoglobin A1c (HbA1c)

High-Frequency Heart Rate Variability (HF HRV)

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

+2 more

SHADES Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: SHADES InterventionExperimental Treatment3 Interventions

The SHADES intervention is a 6-month, modernized, collaborative care intervention in which a multidisciplinary team delivers established insomnia treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that harnesses technology to maximize access to and convenience of effective treatments and to minimize personnel, training, and space requirements. Our Intervention Team consists of an insomnia clinical specialist, a clinical behavioral sleep medicine and CBT-I delivery expert, a sleep research/medicine expert, and the patients' primary care providers. Treatments to be delivered are CBT-I in different modalities - internet, phone, and face-to-face - all of which are empirically supported.

Group II: Active ControlActive Control1 Intervention

Active Control (AC) consists of sleep education and hygiene (study staff), symptom monitoring (study staff), and usual primary care for insomnia (clinical staff).

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,833 Previous Clinical Trials

47,306,296 Total Patients Enrolled

165 Trials studying Coronary Artery Disease

268,832 Patients Enrolled for Coronary Artery Disease

Eskenazi HealthOTHER

11 Previous Clinical Trials

2,634 Total Patients Enrolled

Regenstrief Institute, Inc.OTHER

26 Previous Clinical Trials

98,277 Total Patients Enrolled

1 Trials studying Coronary Artery Disease

1,400 Patients Enrolled for Coronary Artery Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical experiment actively recruiting participants?

"According to the data hosted on clinicaltrials.gov, this study is no longer actively recruiting patients as it was last updated on September 11th 2023. However, there are still 2,800 other studies currently open and welcoming new participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

SHADES Mechanistic Trial

Jesse Stewart 2024. "SHADES Mechanistic Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06041581.

All > Sleep Disorder